whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation
See FDA's updated safety analysis concerning bisphophonates and atrial fibrillation
Patients are asking whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation.
This first came up last year when researchers noted an increase in A fib in patients getting zoledronic acid (Reclast).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote